Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.
Boyce
S
S
Rupniak
N M
NM
Steventon
M J
MJ
Iversen
S D
SD
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects / Q000266:history*; D000818:Animals; D015259:Dopamine Agents / Q000009:adverse effects / Q000266:history*; D018491:Dopamine Agonists / Q000266:history* / Q000627:therapeutic use; D049673:History, 20th Century; D010300:Parkinson Disease / Q000266:history*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000266:history*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000266:history*; D012453:Saimiri
D015259:Dopamine Agents; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine